1

Word Count: 3386

2 Epigenetic and Genetic Profiling of Comorbidity Patterns among Substance 3 Dependence Diagnoses

- 5 Gita A. Pathak ^{1,2}, Robert H. Pietrzak ^{1,2,3}, AnnMarie Lacobelle^{1,2}, Cassie Overstreet^{1,2},
- 6 Frank R. Wendt ^{1,2,4}, Joseph D. Deak^{1,2}, Eleni Friligkou^{1,2}, Yaira Nunez^{1,2}, Janitza L.
- 7 Montalvo-Ortiz^{1,2}, Daniel F. Levey^{1,2}, Henry R. Kranzler⁵, Joel Gelernter^{1,2}, Renato
- 8 Polimanti^{1,2}
- ¹Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
- 10 ²U.S Department of Veteran Affairs Connecticut Healthcare System, West Haven, CT,
- 11 USA
- ³Department of Social and Behavioral Sciences, Yale School of Public Health, New
 Haven, CT, USA
- ⁴Regeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, NY, USA
- 15 ⁵ Center for Studies of Addiction, University of Pennsylvania Perelman School of
- Medicine and the Mental Illness Research, Education and Clinical Center, Crescenz
 VAMC, Philadelphia PA, USA
- 18
- 19
- 20 **Keywords**: Latent class, Methylation, Opioid, Nicotine, Cannabis, Alcohol, Nicotine,
- 21 Substance Use Disorder, Addiction
- 22
- 23 **Correspondence**: Renato Polimanti, PhD. Yale University School of Medicine,
- 24 Department of Psychiatry, 60 Temple, Suite 7A, New Haven, CT 06510, USA. Phone:
- 25 +1 (203) 737-6391; E-mail: renato.polimanti@yale.edu
- 26

27 ABSTRACT

- 28 Objective—This study investigated the genetic and epigenetic mechanisms underlying
- 29 the comorbidity patterns of five substance dependence diagnoses (SDs; alcohol, AD;
- 30 cannabis, CaD; cocaine, CoD; opioid, OD; tobacco, TD).
- 31 Methods—A latent class analysis (LCA) was performed on 31,197 individuals (average
- 32 age 42±11 years; 49% females) from six cohorts to identify comorbid DSM-IV SD
- 33 patterns. In subsets of this sample, we tested SD-latent classes with respect to
- 34 polygenic burden of psychiatric and behavioral traits and epigenome-wide changes in
- 35 three population groups.
- 36 *Results*—An LCA identified four latent classes related to SD comorbidities: AD+TD,
- 37 CoD+TD, AD+CoD+OD+TD (i.e., polysubstance use, PSU), and TD. In the epigenome-
- 38 wide association analysis, SPATA4 cg02833127 was associated with CoD+TD, AD+TD,
- 39 and PSU latent classes. AD+TD latent class was also associated with CpG sites located
- 40 on ARID1B, NOTCH1, SERTAD4, and SIN3B, while additional epigenome-wide
- 41 significant associations with CoD+TD latent class were observed in ANO6 and MOV10
- 42 genes. PSU-latent class was also associated with a differentially methylated region in
- 43 LDB1. We also observed shared polygenic score (PGS) associations for PSU, AD+TD,
- 44 and CoD+TD latent classes (i.e., attention-deficit hyperactivity disorder, anxiety,
- 45 educational attainment, and schizophrenia PGS). In contrast, TD-latent class was
- 46 exclusively associated with posttraumatic stress disorder-PGS. Other specific
- 47 associations were observed for PSU-latent class (subjective wellbeing-PGS and
- 48 neuroticism-PGS) and AD+TD-latent class (bipolar disorder-PGS).
- 49 *Conclusions*—We identified shared and unique genetic and epigenetic mechanisms
 50 underlying SD comorbidity patterns. These findings highlight the importance of modeling
 51 the co-occurrence of SD diagnoses when investigating the molecular basis of addiction52 related traits.
- 53

54 INTRODUCTION

Substance dependence (SD) is a significant public health concern, affecting more than 55 56 40 million individuals in the United States¹. The most prevalent SDs are related to 57 alcohol (AD), cannabis (CaD), cocaine (CoD), opioid (OD), and tobacco (TD). Patients 58 with SDs often exhibit misuse of more than one substance, which complicates treatment and recovery efforts². The comorbidity of SDs exacerbates a range of negative health 59 60 outcomes, making it critical to understand the patterns of SD comorbidities^{2,3}. The 61 heterogeneity of SD comorbidity patterns poses a major challenge in identifying the 62 mechanistic underpinnings of these disorders. SD patterns can stem from a range of 63 factors, including shared genetic predisposition, environmental influences, and 64 sociocultural context. Genome-wide association studies (GWAS) and epigenome-wide 65 association studies (EWAS) uncovered mechanisms contributing to the predisposition to SDs ⁴⁻¹⁰. To date, these previous efforts largely focused on single SDs, limiting our 66 67 understanding of the real world in which patients are generally affected by multiple SDs. This study identified comorbidity patterns among AD, CaD, CoD, OD, and TD using a 68 69 latent class analysis (LCA, a method that aims to identify more homogeneous 70 subgroups in heterogeneous data). Then, we investigated SD-latent classes with 71 respect to methylation changes and polygenic burdens related to psychiatric and 72 behavioral traits (FIGURE 1). The findings shared and unique epigenetic and genetic 73 profiles that underlie SD comorbidity patterns.

74

75 METHODS

76 Cohorts

- 77 We investigated six cohorts with information regarding DSM-IV diagnoses of AD, CaD,
- 78 CoUD, OD, and TD (**TABLE 1**). In addition to the Yale-Penn cohort¹¹⁻¹⁵, we analyzed five
- 79 datasets available from NCBI's Database of Genotypes and Phenotypes (dbGaP):
- 80 'Study of Addiction: Genetics and Environment' [phs000092] ¹⁶, 'Genome-Wide
- 81 Association Study of Heroin Dependence' [phs000277] ¹⁷, 'Genetic Architecture of
- 82 Smoking and Smoking Cessation' [phs000404]¹⁸, 'CIDR, NCI, NIDA Sequencing of

83 Targeted Genomic Regions Associated with Smoking' [phs000813] ¹⁸, and 'Nicotine

Addiction Genetics and Correlates' [phs001299] ¹⁹. Overall, we analyzed SD data

collected from 31,197 individuals (average age 42±11 years; 49% females).

86

87 Latent Class Analysis

LCA was performed in R version 4.1 using the poLCA R package ²⁰for the primary
 investigation and Mplus software ²¹for validation. The number of latent classes was
 identified based on the lowest Akaike Information Criterion (AIC), Bayesian Information

91 Criterion (BIC), Likelihood ratio/deviance statistic (G²), and Pearson Chi-square

92 goodness of fit statistic (χ^2). The probability threshold to assign participants with SDs in

93 classes was identified using MANOVA by comparing the probability of SD cases across

94 the latent classes identified in the best-fitting model.

95

96 Genetic Data

97 Genotype data from the six studies was cleaned by removing individuals with

98 mismatched biological sex, low genotyping rate, heterozygosity, and relatedness. Single

99 nucleotide polymorphisms (SNPs) were removed based on minor allele frequency

100 (MAF<1%), Hardy-Weinberg equilibrium ($p<1\times10^{-6}$), and sample missingness (<10%).

101 Continental genetic ancestry was estimated against a combined reference panel

102 including 1000 Genomes Project and Human Genome Diversity Project ²². Genetic

103 relatedness and within-ancestry principal components were generated using KING ²³.

104 Genotype data from each study was imputed using TopMed Imputation server ²⁴.

105 Because large-scale psychiatric/behavioral GWAS are present only for populations of

106 European descent, we limited the PGS analysis to this population group. After quality

107 control (QC), genetic data from 7,659 individuals of European descent were available108 for PGS testing.

109

110 Epigenetic Data

111 DNA methylation data were available for a subset of the Yale-Penn participants (n=886). 112 Briefly, DNA was extracted from whole blood of Yale-Penn participants collected at the 113 time of recruitment using Paxgene Blood DNA Kit (Qiagen, MD, USA). Bisulfite 114 conversion of the extracted DNA was performed using the EZ-96 DNA methylation kit 115 (Zymo Research, CA, USA) and subsequently processed on the Infinium ® 116 MethylationEPIC BeadChip array (Illumina, San Diego, CA USA) which assesses the 117 methylation status of over 850,000 CpG sites. Raw signal intensity data (IDAT) files 118 from the array were uploaded and processed in R Studio. These files provided beta 119 values, indicating DNA methylation levels at specific CpG sites, with values ranging 120 from 0 (unmethylated) to 1 (fully methylated). Primary QC steps removed CpG sites with 121 low detection p-values, missing beads, close proximity to SNPs, multi-hit sites, and non-122 autosomal sites. The beta values of the remaining CpG sites were normalized using the beta mixture quantile (BMIQ) method ²⁵. Batch effects were identified using singular 123 124 vector decomposition. Technical batch effects related to array and slide were corrected using ComBat function in sva R package ²⁶. DNA Methylation data were used to 125 126 estimate blood cell-type compositions (i.e., CD8+T, CD4+T, natural killer, B, monocytes, and neutrophils)²⁷, and smoking status²⁸. 127

128

129 Epigenome-wide association analysis

130 After QC, we tested 657,226 CpG sites for differential methylation with respect to SD-131 latent classes in three population groups (European-descent, EUR, n=481; African-132 descent, AFR n=339; Admixed-Americans, AMR n=66). Association analysis for CpG 133 sites was performed on M-values (transformed beta values) using empirical Bayes methods implemented in the limma R package²⁹. The analysis was adjusted for age, 134 sex, genotype-derived principal components 1-10, methylation-based smoking score ²⁸. 135 136 and proportions of blood cell types (i.e., CD8+T, CD4+T, natural killer, B, monocytes, and neutrophils). Inflation was calculated using the QQperm R package ³⁰. For the 137 138 ancestry-stratified EWAS of each SD-latent class, the minimum sample size was 15. The meta-analysis across all ancestries was performed using GWAMA³¹ to improve 139 140 statistical power. For each EWAS cross-ancestry meta-analysis, genomic control

141 correction was applied to epigenome-wide association statistics when lambda was
 142 >1.05. Differentially methylated regions were identified using the dmrff R package ³².
 143 Regions were defined as consisting of 2 to 30 CpG sites within 500 base pairs. False

discovery rate (FDR q<0.05) was used to adjust for multiple testing. The CpG sites were

145 further investigated using information available from the EWAS Catalogue³³ (available

146 at <u>https://www.ewascatalog.org/</u>). We also assessed brain-blood concordance of the

147 CpG sites identified using BECon application ³⁴.

148

149 Polygenic Score Analysis

150 PGSs were derived from GWAS of attention deficit/hyperactivity disorder (ADHD;

151 N=225,534) ³⁵, anxiety (N=1,096,458) ³⁶, autism spectrum disorder (N=46,350) ³⁷,

152 bipolar disorder (N=413,466)³⁸, depression (N=1,035,760)³⁹, educational attainment

153 $(N=765,283)^{40}$, neuroticism $(N=380,000)^{41}$, posttraumatic stress disorder (PTSD;

154 N=1,222,882) ⁴², schizophrenia (N=320,404) ⁴³, and subjective well-being (N=298,420)

⁴⁴. The polygenic scores were calculated using PRS-CS⁴⁵, with the 1000 Genomes

reference panel for linkage disequilibrium, scaled to have mean of 0 and a unit of 1

157 standard deviation. In each cohort, PGSs were tested with respect to SD-latent classes,

158 including age, sex, and top-ten within-ancestry principal components as covariates. For

each SD-latent class, cohort-specific PGS associations were meta-analyzed using meta

160 R package⁴⁶. Bonferroni-corrected threshold of $p < 1.25 \times 10^{-3}$ was used to adjust for the

161 number of PGS association tests performed (n=40).

162

163 **RESULTS**

164 Latent class analysis of SDs

165 With respect to comorbidity patterns among DSM-IV based AD, CaD, CoD, OD and TD,

166 the model with five latent classes was identified as the best fitting because of the lowest

167 value combination of AIC, BIC, G^2 , and χ^2 metrics (**SUPPLEMENTARY TABLE 1**).

168 Considering a posterior probability≥70% (FIGURE 2; SUPPLEMENTARY FIGURE 1), we

169 stratified the sample of 31,197 subjects across the five SD-latent classes. Because of

the high case-posterior probability for AD and TD (97% and 75%, respectively), 6,487

- 171 participants were included in the AD+TD-latent class. A total of 1,170 participants were
- assigned to the CoD+TD-latent class, because of the high case-posterior probability of
- these SDs (85% and 70%, respectively). We also observed 2,090 participants related to
- 174 a polysubstance use disorder (PSU)-latent class, which had high case-posterior
- probabilities for AD (95%), CoD (99%), OD (100%), and TD (96%). An additional latent
- 176 class including 1,162 individuals showed high posterior probability only for TD (100%).
- 177 Finally, there were 11,759 participants assigned to a latent class with high control-
- 178 posterior probability for all SDs (i.e., 89% AD, 80% CaD, 94% CoD, 72% TD, 99% OD).
- 179 CaD did not show high case-posterior probability in any of the SD-latent classes
- 180 (SUPPLEMENTARY TABLE 2).
- 181

182 Epigenome-wide association study of SD latent classes

- 183 Relative to the control-latent class group, we performed cross-ancestry EWAS meta-
- 184 analyses of AD+TD, CoD+TD, PSU-latent classes in 886 individuals, identifying seven
- 185 CpG associations (FIGURE 3; SUPPLEMENTARY FIGURE 2; SUPPLEMENTARY TABLES 3-6).
- 186 TD-latent class was excluded from this analysis because of the small sample size. After
- 187 FDR multiple testing correction (FDR q<0.05), SPATA4 cg02833127 (location: 1st exon,
- 188 5'UTR) was associated with the three SD-latent classes investigated (i.e., AD+TD β =-
- 189 0.49, P=9.9×10⁻⁵⁰; CoD-TD β=-0.3, *P*= 2.93×10⁻¹¹; PSU β=-0.24, *P*=3.19×10⁻¹¹). Four
- additional CpG sites were associated with the AD+TD-latent class: *SIN3B* cg06815056
- 191 (location: TSS200; β =0.23, P=2.91×10⁻⁷), *ARID1B* cg19436567 (location: 1st exon;
- 192 β=0.22, P=1.47×10⁻⁷), *SERTAD4* cg20270863 (location: TSS200, 5'UTR; β=0.16,
- 193 P= 3.42×10^{-7}) and *NOTCH1* cg13725899 (location: gene body; β =0.16, P= 8.69×10^{-8}).
- 194 Two additional FDR-significant CpG associations were detected with respect to
- 195 CoD+TD latent class: *MOV10* cg08355353 (Location gene body; β =0.43, *P*=1.08×10⁻⁷)
- 196 and ANO6 cg09909775 (Location: 1stExon, 5'UTR; β =0.50; P=2.03×10⁻⁷). Considering
- 197 information available from the EWAS catalog (**SUPPLEMENTARY TABLE 7**), these CpG
- 198 sites were previously identified in the context of aging (cg08355353, cg06815056,
- 199 cg13725899, cg19436567, and cg02833127), rheumatoid arthritis (cg06815056),

- Alzheimer's disease (cg13725899), renal carcinoma (cg20270863), and molecular regulation (cg06815056, cg13725899, and cg19436567).
- 202 We observed cross-ancestry heterogeneity in the association between SPATA4
- 203 cg02833127 and AD+TD-latent class (I^2 =88%, heterogeneity p<2×10⁻⁴) where the
- effect was more negative in EUR (β = -0.60, 95%CI=-0.67 -0.52) than in AFR (β = -
- 205 0.33, 95%CI=-0.43 -0.23). Conversely, no cross-ancestry heterogeneity was observed
- in *SPATA4* cg02833127 association with CoD+TD and PSU-latent classes and also for
- the other FDR-significant CpG associations (heterogeneity-p>0.05; **FIGURE 3**).
- 208 In addition to CpG association, we also observed one FDR-significant differentially
- 209 methylated region (chr10:102120371-102120478; Z=5.466; P= 4.60x10⁻⁸) related to
- 210 PSU-latent class, spanning 2 CpG sites (cg15320455 TSS200; cg17106419 –
- 211 TSS200) within *LDB1* gene (**SUPPLEMENTARY TABLE 8**).
- 212 Comparing brain-blood methylation patterns of the identified CpG sites
- 213 (SUPPLEMENTARY FIGURE 2), we observed correlation estimates in the top-90th
- 214 percentile for MOV10 cg08355353 (rho=0.36 in the Brodmann area (BA) 7), SERTAD4
- 215 cg20270863 (rho=0.38 in BA20), *SIN3B* cg06815056 (rho=-0.45 in BA20), *SPATA4*
- 216 cg02833127 (rho=-0.44 in BA7), and ARID1B cg19436567 (rho=0.49 in BA10; rho=-
- 217 0.35 in BA20)
- 218
- 219 Polygenic burden associations with SD-latent classes
- 220 Assessing the pleiotropy across SD-latent classes, we observed different patterns of
- 221 psychiatric-behavioral PGS associations (FIGURE 4; SUPPLEMENTARY TABLE 9). After
- Bonferroni multiple testing correction ($p < 1.25 \times 10^{-3}$), PTSD was the only PGS
- 223 associated across the four SD-latent classes (SUPPLEMENTARY TABLE 9). TD-latent
- class was only associated with PTSD PGS (Odds ratio, OR=1.32, p= 7.24×10^{-4}). In
- 225 contrast, PSU, AD+TD, and CoD+TD latent classes showed shared PGS associations
- with ADHD (positive relationship), anxiety (positive relationship), educational attainment
- 227 (inverse relationship), and schizophrenia (positive effect) with comparable effect sizes
- 228 (SUPPLEMENTARY TABLE 9). In addition to shared pleiotropic mechanisms, we also

- 229 observed specific PGS associations. PSU-latent class was uniquely associated with
- PGS of neuroticism (OR=1.21; P= 2.62×10^{-6}) and subjective wellbeing (OR=0.86;
- P= 2.12×10^{-4}) with opposite effect directions. AD+TD-latent class was uniquely
- associated with bipolar disorder-PGS (OR=1.14; P= 1.39×10^{-5}).
- 233 Because PGS associations were estimated from the meta-analysis of cohorts with
- 234 different characteristics (TABLE 1), we also estimated cross-cohort heterogeneity within
- the PGS effects. After Bonferroni correction, there was significant heterogeneity
- 236 (heterogeneity Q-P< 1.25×10^{-3}) in the association between PTSD PGS and AD+TD-
- 237 latent class (I2=0.89; tau²=0.05; Q=28.4, Q-df=3, Q-p= 3×10^{-6}) and between
- educational attainment PGS and TD-latent class (I2=0.84; tau²=0.12; Q=18.9, Q-df=2,
- 239 Q-P= 2.81×10^{-4}). In the first, the heterogeneity was driven by two-studies, phs000404
- and phs001299 (SUPPLEMENTARY TABLES 9 AND 10). The meta-analyzed effect
- 241 association between educational attainment PGS and TD-latent class was only
- 242 nominally significant (OR=0.82, P=0.01) and its Bonferroni-significant heterogeneity was
- driven by two studies, Yale-Penn and phs000092 (SUPPLEMENTARY TABLES 9 AND 10).

244

245 **DISCUSSION**

246 SDs have a pervasive negative impact on individuals, families, and society at large. 247 More severe consequences are experienced by individuals with co-occurring SDs. which represent the largest portion of affected individuals⁴⁷. To date, most genomic 248 studies modeled singular SD cases without considering co-occurring SDs ^{9, 10}. Recently, 249 250 large-scale GWAS datasets have been used to investigate the shared pathogenesis across SDs and related phenotypes^{48, 49}. While the findings of these studies increased 251 252 our understanding of the molecular mechanisms responsible for polysubstance 253 comorbidities, more efforts are needed to dissect the dynamics underlying different 254 patterns of SD co-occurrence. Applying LCA, previous observational studies of 255 nationally representative samples, treatment-seeking populations, and cohorts enriched for SD cases identified latent classes reflecting different polysubstance patterns ⁵⁰⁻⁵⁴. 256 257 Building on this evidence, we identified four SD-latent classes in a sample of >30,000

individuals and then investigated genetic and epigenetic mechanisms associated withthe different SD comorbidity patterns.

260 Investigating epigenome-wide differences, our study revealed several differentially 261 methylated sites with shared and distinct associations across SD-latent classes. 262 SPATA4 cg02833127 was consistently hypomethylated among cases in the AD+TD, 263 CoD+TD, and PSU latent classes. This CpG site has been associated with aging trajectories from birth to late adolescence with methylation decreasing later in life ⁵⁵. 264 265 SPATA4 locus has been also identified in a large-scale GWAS of educational attainment⁴⁰. While the function of this locus is still unknown, a study observed aging-266 related changes in mice overexpressing this gene ⁵⁶. In this context, SPATA4 267 cq02833127 association across SD-latent classes points to the possible impact of SD 268 269 comorbidities on aging-related regulatory mechanisms. We observed cross-ancestry 270 heterogeneity in the association of this CpG site with AD+TD latent class with greater 271 effect in EUR than AFR. This supports that SD comorbidities may affect biological 272 pathways differently among population groups. Alternatively, cross-ancestry 273 heterogeneity of the association between SPATA4 cq02833127 and AD+TD latent class 274 may reflect the contribution of environmental factors acting differently across population

275 groups.

276 The AD+TD-latent class was uniquely associated with four additional CpG sites. Among 277 them, NOTCH1 cg13725899 was previously identified by multiple EWAS⁵⁷⁻⁶⁰. Two of 278 which were conducted using brain tissues and linked this CpG site with fetal brain development ⁵⁸ and Alzheimer's disease ⁶⁰. Other *NOTCH1* CpG sites have been 279 reported in EWAS of AD ⁷ and tobacco smoking ⁶¹. The NOTCH1 locus was also 280 281 identified in GWAS of brain-related outcomes, including cortical thickness and Alzheimer's disease^{62, 63}. The protein product of this gene plays an important role in a 282 signaling pathway involved in neurodevelopmental processes⁶⁴. *NOTCH1* may play a 283 role in SD pathogenesis through its negative regulation of GABA receptors ⁶⁵. Also, the 284 285 other genes mapping to AD+TD-associated CpG sites (i.e., ARID1B and SIN3B) appear to play important regulatory roles in the central nervous system^{66, 67}. Additionally, there 286

were DNA methylation changes in *ARID1B* and *SIN3B* have been previously linked to
 cigarette smoking ⁶⁸⁻⁷¹ and alcohol use ⁷²⁻⁷⁴.

The CoD+TD latent class showed specific epigenetic associations in *ANO6 and MOV10*. The latter locus has been linked to regulatory processes related to neuronal development and function⁷⁵. Multiple GWAS identified *MOV10* in relation to cortical surface area, cortical thickness, and brain connectivity⁷⁶⁻⁷⁸. In contrast, *ANO6* gene does not appear to play a specific role in brain function, but is involved in phospholipid regulation occurring in various biological systems⁷⁹. Previous EWAS identified other *ANO6* and *MOV10* CpG sites as associated with tobacco smoking ^{80, 81}.

In addition to identifying individual CpG sites, we also observed a differentially
methylated region mapping to *LDB1* that was associated with the PSU-latent class. This
locus appears to be required for the early development of the dorsal telencephalon and
the thalamus ⁸². Additionally, *LDB1* regulates gene expression in olfactory sensory
neurons ⁸³. The brain gene expression of this locus has been identified as negatively
correlated with cocaine-seeking response in rats ⁸⁴.

302 Overall, our EWAS findings support the association of SD-latent classes with genes involved in brain developmental processes. The applicability of our blood-based findings 303 304 into brain mechanisms is supported by the high blood-brain correlation observed for several of the CpG sites identified (i.e., MOV10 cq08355353, SERTAD4 cq20270863, 305 306 SIN3B cq06815056, SPATA4 cq02833127, and ARID1B cq19436567). In some cases, 307 genes we identified here (but with different CpG sites) were reported as associated by 308 previous EWAS of tobacco smoking. Because we controlled for the effect of tobacco 309 smoking on DNA methylation, the epigenetic associations identified in our study likely 310 reflect SD comorbidities rather than the co-occurrence of tobacco smoking. Indeed, we 311 did not identify any association between SD-latent classes and AHRR locus, which is the most established epigenetic biomarker for tobacco smoking ⁸⁵. 312

313 We also identified genetic associations linking SD comorbidity patterns to other

314 psychiatric disorders. PTSD was the only PGS showing Bonferroni significant

315 association across the four SD-latent classes. This may support the role of mechanisms

related to trauma response across SD comorbidity patterns. This is also in line with the

317 well-known impact of stress response on biological mechanisms involved in SD pathogenesis⁸⁶. TD-latent class was only associated with PTSD PGS. This may be due 318 319 to the small sample size of the TD-latent class. Alternatively, it may also reflect the 320 limited pleiotropy of this SD pattern with other mental illnesses. With respect to the other 321 PGS associations shared among the remaining SD-latent classes, the relationships 322 observed with respect to neurodevelopmental disorders (i.e., ADHD and schizophrenia) 323 appear to converge with the EWAS findings, highlighting the potential role of altered 324 neurodevelopmental processes in the shared pathogenesis among SD comorbidity 325 patterns. Consistent with this hypothesis, previous studies highlighted how early-life 326 adversity affects the development of brain reward and stress circuits increasing 327 addiction vulnerability⁸⁷.

328 In addition to shared pleiotropic mechanisms, we also observed PGS associations 329 specific to certain SD-latent classes. Bipolar-disorder PGS was uniquely associated with 330 the AD+TD latent class. Multiple studies pointed to neural reward circuit dysfunction as the risk factor shared between bipolar disorder and SDs⁸⁸. The PSU-latent class 331 332 showed two specific PGS associations: negative association with subjective well-being, 333 and positive association with neuroticism. These may be related to poorer outcomes 334 that are seen in individuals affected by the comorbidities of four SDs than those observed in subjects with only two comorbid SDs^{89, 90}. In a previous study, a genetically 335 336 inferred addiction factor shared across AD, TD, CaD, and TD was highly genetically correlated with neuroticism ⁹⁰. 337

338 Our study has multiple limitations. The cohorts investigated were specifically recruited to 339 study SD genetics, overrepresenting the samples for cases. This may reduce the 340 generalizability of the SD-latent classes identified. The PGS analysis was limited to 341 individuals of European descent, because of the lack of large-scale GWAS to derive 342 statistically powerful PGS for other population groups. In the epigenome-wide analysis, 343 we conducted a cross-ancestry meta-analysis assessing heterogeneity among the 344 population groups. However, we had limited power to investigate ancestry-specific 345 epigenetic effects. Similarly, we focused only on five main SDs because of the limited

information on other substances in the cohorts investigated (e.g., hallucinogens,

347 inhalants, sedatives, and amphetamines).

348 Notwithstanding these limitations, the present study provides new insights into genetic

349 and epigenetic mechanisms contributing to in SD comorbidity patterns. Our findings

350 support the potential role of brain developmental processes on SD pathogenesis and

- 351 suggest possible mechanisms that differentiate the co-occurrence of different SD
- 352 combinations. Building on this evidence, further studies are needed to extend these
- 353 findings elucidating the dynamics underlying polysubstance use disorders.
- 354

355 ACKNOWLEDGEMENTS

This study is supported by the National Institute on Drug Abuse, R33 DA047527. GAP
acknowledges support from the Yale Biological Sciences Training Program (T32
MH014276), Alzheimer's Association (AARF-22-967171), NIH National Institute of Aging

359 (K99AG078503), Yale Franke Fellowship in Science & Humanities, and Yale Women's

360 Faculty Forum Award. RP acknowledges grants from the National Institute of Mental

361 Health (RF1 MH132337) and One Mind Rising Star Award. JDD acknowledges support

by the National Institute on Drug Abuse K01 DA058807. DFL is funded by a Career

363 Development Award from the US Department of Veterans Affairs Office of Research and

364 Development (1IK2BX005058). HK acknowledges support from the Department of

- 365 Veterans Affairs (VISN 4 MIRECC and I01 BX004820). JLMO acknowledges support
- from U.S. Department of Veterans Affairs via 1IK2CX002095 and NIDA R21DA050160.
- 367 JG reports support from the Department of Veterans Affairs (5IO1CX001849-04 and the
- 368 VISN 1 New England MIRECC) and NIH/NIDA (2R01DA037974, 1R01DA058862-01).
- 369

370 CONFLICT OF INTEREST

371 RP received a research grant from Alkermes outside the scope of the present study. RP

and JG are paid for their editorial work on the journal Complex Psychiatry. JG and HRK

are holders of U.S. patent 10,900,082 titled: "Genotype-guided dosing of opioid

agonists," issued 26 January 2021. HRK is a member of advisory boards for Dicerna

- 375 Pharmaceuticals, Sophrosyne Pharmaceuticals, Enthion Pharmaceuticals, and
- 376 Clearmind Medicine; a consultant to Sobrera Pharmaceuticals and Altimmune; the
- 377 recipient of research funding and medication supplies for an investigator-initiated study
- 378 from Alkermes; a member of the American Society of Clinical Psychopharmacology's
- 379 Alcohol Clinical Trials Initiative, which was supported in the last three years by
- 380 Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, Otsuka, and Pear Therapeutics.
- 381 FRW is an employee of Regeneron Pharmaceuticals with no conflict of interest related
- to any intellectual property of the company. The other authors have no competing
- interests to report.

Table 1: Characteristics of the cohorts investigated.											
	Ν	Age, mean±SD	Female %	AD, N	CaD, N	CoD, N	OD, N	TD, N			
phs000092	4,121	39±9	54	1,946	753	1,130	304	1,856			
phs000277	3,515	46±10	42	55	4	0	0	205			
phs000404	1,527	37±6	59	204	222	149	21	1,239			
phs000813	2,969	52±7	60	516	354	210	57	1,844			
phs001299	3,508	50±14	51	493	134	6	32	1,367			
Yale-Penn	15,557	40±12	46	7,481	3,897	8,662	4,379	8,219			
Total	31,197	42±11	49	10,695	5,364	10,157	4,793	14,730			

385

387 FIGURE LEGENDS

Figure 1. Study Design. An overview of the study design showing five substance dependence (SD) diagnoses assessed in six different cohorts and used to identify latent classes related to their comorbidities. Each of the SD latent classes was compared against the control group in the epigenome-wide association study and estimating genetic burden of ten psychiatric and behavioral traits.

393 Figure 2. Distribution of case- and control-posterior probability across SDs in the

394 **five-latent class model.** The x-axis (top) shows each of the substance dependence

diagnoses, and the y-axis shows the probability value of cases and controls for each of

the five SDs across each latent class shown on the left. Details of the statistical

397 comparisons are shown in Supplementary Figure 1.

Fig 3. Epigenome-wide association study of SD latent classes. Forest Plots show
meta-analyzed effect sizes of the significant CpG sites across ancestral groups; EUR –
European descent; AFR – African descent; AMR – Admixed Americans.

Fig 4. Association of polygenic scores of psychiatric and behavioral traits with SD latent classes. Forest plot showing meta-analyzed associations of ten traits with SUD latent classes. The x-axis shows odds ratio as points and 95% confidence intervals as lines. The Bonferroni-significant associations are marked with green, while others are indicated in grey. Details regarding PGS associations are shown in Supplementary Table 9.

408 **REFERENCES**

- 409 1. Substance Use & Substance Use Disorders.
- 410 <u>https://wwwnc.cdc.gov/travel/yellowbook/2024/additional-</u>
- 411 <u>considerations/substance-use</u>, 2024, Accessed Date Accessed 2024 Accessed.
- 412 2. Abuse NIoD. Common Comorbidities with Substance Use Disorders Research
 413 Report. NCBI: Bethesda (MD), 2020.
- 414 3. Owens PL, Heslin KC, Fingar KR, Weiss AJ. Co-occurrence of Physical Health
 415 Conditions and Mental Health and Substance Use Conditions Among Adult
 416 Inpatient Stays, 2010 Versus 2014. *Healthcare Cost and Utilization Project*417 (*HCUP*) Statistical Briefs: Rockville (MD), 2006.
- 418 4. Stephenson M, Bollepalli S, Cazaly E, Salvatore JE, Barr P, Rose RJ *et al.*419 Associations of Alcohol Consumption With Epigenome-Wide DNA Methylation 420 and Epigenetic Age Acceleration: Individual-Level and Co-twin Comparison 421 Analyses. *Alcohol Clin Exp Res* 2021; **45**(2): 318-328.
- 422 5. Montalvo-Ortiz JL, Cheng Z, Kranzler HR, Zhang H, Gelernter J. Genomewide
 423 Study of Epigenetic Biomarkers of Opioid Dependence in European-American
 424 Women. *Sci Rep* 2019; 9(1): 4660.
- 425 6. Poisel E, Zillich L, Streit F, Frank J, Friske MM, Foo JC *et al.* DNA methylation in
 426 cocaine use disorder-An epigenome-wide approach in the human prefrontal
 427 cortex. *Front Psychiatry* 2023; **14:** 1075250.
- 428 7. Lohoff FW, Roy A, Jung J, Longley M, Rosoff DB, Luo A *et al.* Epigenome-wide
 429 association study and multi-tissue replication of individuals with alcohol use
 430 disorder: evidence for abnormal glucocorticoid signaling pathway gene
 431 regulation. *Mol Psychiatry* 2021; **26**(6): 2224-2237.
- 432 8. Kember RL, Hartwell EE, Xu H, Rotenberg J, Almasy L, Zhou H *et al.* Phenome433 wide Association Analysis of Substance Use Disorders in a Deeply Phenotyped
 434 Sample. *Biol Psychiatry* 2023; **93**(6): 536-545.
- 435 9. Deak JD, Johnson EC. Genetics of substance use disorders: a review. *Psychol*436 *Med* 2021; **51**(13): 2189-2200.
- 437 10. Gelernter J, Polimanti R. Genetics of substance use disorders in the era of big data. *Nat Rev Genet* 2021; 22(11): 712-729.
- 439 11. Gelernter J, Kranzler HR, Sherva R, Almasy L, Koesterer R, Smith AH *et al.*440 Genome-wide association study of alcohol dependence:significant findings in
 441 African- and European-Americans including novel risk loci. *Mol Psychiatry* 2014;
 442 **19**(1): 41-49.
- 443 12. Gelernter J, Kranzler HR, Sherva R, Koesterer R, Almasy L, Zhao H *et al.*444 Genome-wide association study of opioid dependence: multiple associations
 445 mapped to calcium and potassium pathways. *Biol Psychiatry* 2014; **76**(1): 66-74.

446 13. Gelernter J, Kranzler HR, Sherva R, Almasy L, Herman AI, Koesterer R *et al.*447 Genome-wide association study of nicotine dependence in American populations:
448 identification of novel risk loci in both African-Americans and European449 Americans. *Biol Psychiatry* 2015; **77**(5): 493-503.

- 450 14. Gelernter J, Sherva R, Koesterer R, Almasy L, Zhao H, Kranzler HR *et al.*451 Genome-wide association study of cocaine dependence and related traits:
 452 FAM53B identified as a risk gene. *Mol Psychiatry* 2014; **19**(6): 717-723.
- 453 15. Sherva R, Wang Q, Kranzler H, Zhao H, Koesterer R, Herman A *et al.* Genome454 wide Association Study of Cannabis Dependence Severity, Novel Risk Variants,
 455 and Shared Genetic Risks. *JAMA Psychiatry* 2016; **73**(5): 472-480.
- Rice JP, Hartz SM, Agrawal A, Almasy L, Bennett S, Breslau N *et al.* CHRNB3 is
 more strongly associated with Fagerstrom test for cigarette dependence-based
 nicotine dependence than cigarettes per day: phenotype definition changes
 genome-wide association studies results. *Addiction* 2012; **107**(11): 2019-2028.
- Nelson EC, Lynskey MT, Heath AC, Wray N, Agrawal A, Shand FL *et al.* ANKK1,
 TTC12, and NCAM1 polymorphisms and heroin dependence: importance of
 considering drug exposure. *JAMA Psychiatry* 2013; **70**(3): 325-333.
- 463 18. Bierut LJ, Madden PA, Breslau N, Johnson EO, Hatsukami D, Pomerleau OF *et*464 *al.* Novel genes identified in a high-density genome wide association study for
 465 nicotine dependence. *Hum Mol Genet* 2007; **16**(1): 24-35.
- 466 19. Pergadia ML, Agrawal A, Heath AC, Martin NG, Bucholz KK, Madden PA.
 467 Nicotine withdrawal symptoms in adolescent and adult twins. *Twin Res Hum*468 *Genet* 2010; **13**(4): 359-369.
- 469 20. Linzer DA, Lewis JB. poLCA: An R Package for Polytomous Variable Latent
 470 Class Analysis. *Journal of Statistical Software* 2011; **42**(10): 1 29.
- 471 21. Finch WH, Bronk KC. Conducting Confirmatory Latent Class Analysis Using
 472 Mplus. *Structural Equation Modeling: A Multidisciplinary Journal* 2011; **18**(1):
 473 132-151.
- Wendt FR, Pathak GA, Vahey J, Qin X, Koller D, Cabrera-Mendoza B *et al.*Modeling the longitudinal changes of ancestry diversity in the Million Veteran
 Program. *Hum Genomics* 2023; **17**(1): 46.
- 477 23. Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen WM. Robust
 478 relationship inference in genome-wide association studies. *Bioinformatics* 2010;
 479 26(22): 2867-2873.
- 480 24. Das S, Forer L, Schonherr S, Sidore C, Locke AE, Kwong A *et al.* Next481 generation genotype imputation service and methods. *Nat Genet* 2016; **48**(10):
 482 1284-1287.
- 483 25. Teschendorff AE, Marabita F, Lechner M, Bartlett T, Tegner J, Gomez-Cabrero D
 484 *et al.* A beta-mixture quantile normalization method for correcting probe design

- 485 bias in Illumina Infinium 450 k DNA methylation data. *Bioinformatics* 2013; 29(2):
 486 189-196.
- 487 26. Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for
 488 removing batch effects and other unwanted variation in high-throughput
 489 experiments. *Bioinformatics* 2012; **28**(6): 882-883.
- 490 27. Houseman EA, Accomando WP, Koestler DC, Christensen BC, Marsit CJ, Nelson
 491 HH *et al.* DNA methylation arrays as surrogate measures of cell mixture
 492 distribution. *BMC Bioinformatics* 2012; **13:** 86.
- 493 28. Bollepalli S, Korhonen T, Kaprio J, Anders S, Ollikainen M. EpiSmokEr: a robust classifier to determine smoking status from DNA methylation data. *Epigenomics* 2019; **11**(13): 1469-1486.
- 496 29. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W *et al.* limma powers
 497 differential expression analyses for RNA-sequencing and microarray studies.
 498 *Nucleic Acids Res* 2015; **43**(7): e47.
- 49930.Turner SD. qqman: an R package for visualizing GWAS results using Q-Q and500manhattan plots. Journal of Open Source Software 2018; 3.
- 501 31. Mägi R, Morris AP. GWAMA: software for genome-wide association meta-502 analysis. *BMC Bioinformatics* 2010; **11**(1): 288.
- 503 32. Suderman M, Staley JR, French R, Arathimos R, Simpkin A, Tilling K. dmrff:
 504 identifying differentially methylated regions efficiently with power and control.
 505 bioRxiv 2018: 508556.
- 33. Battram T, Yousefi P, Crawford G, Prince C, Sheikhali Babaei M, Sharp G *et al.*The EWAS Catalog: a database of epigenome-wide association studies. *Wellcome Open Res* 2022; **7:** 41.
- 509 34. Edgar RD, Jones MJ, Meaney MJ, Turecki G, Kobor MS. BECon: a tool for
 510 interpreting DNA methylation findings from blood in the context of brain.
 511 *Translational psychiatry* 2017; **7**(8): e1187.
- 512 35. Demontis D, Walters GB, Athanasiadis G, Walters R, Therrien K, Nielsen TT *et al.* Genome-wide analyses of ADHD identify 27 risk loci, refine the genetic architecture and implicate several cognitive domains. *Nat Genet* 2023; **55**(2): 198-208.
- 516 36. Friligkou E, Løkhammer S, Cabrera-Mendoza B, Shen J, He J, Deiana G *et al.*517 Gene Discovery and Biological Insights into Anxiety Disorders from a Multi518 Ancestry Genome-wide Association Study of >1.2 Million Participants.
 519 *medRxiv* 2024: 2024.2002.2014.24302836.
- 520 37. Grove J, Ripke S, Als TD, Mattheisen M, Walters RK, Won H *et al.* Identification
 521 of common genetic risk variants for autism spectrum disorder. *Nat Genet* 2019;
 522 51(3): 431-444.

- 523 38. Mullins N, Forstner AJ, O'Connell KS, Coombes B, Coleman JRI, Qiao Z *et al.*524 Genome-wide association study of more than 40,000 bipolar disorder cases
 525 provides new insights into the underlying biology. *Nat Genet* 2021; **53**(6): 817526 829.
- 39. Als TD, Kurki MI, Grove J, Voloudakis G, Therrien K, Tasanko E *et al.* Depression
 pathophysiology, risk prediction of recurrence and comorbid psychiatric disorders
 using genome-wide analyses. *Nat Med* 2023; **29**(7): 1832-1844.
- 530 40. Okbay A, Wu Y, Wang N, Jayashankar H, Bennett M, Nehzati SM *et al.* Polygenic
 531 prediction of educational attainment within and between families from genome532 wide association analyses in 3 million individuals. *Nat Genet* 2022; **54**(4): 437533 449.
- 534 41. Kim Y, Saunders GRB, Giannelis A, Willoughby EA, DeYoung CG, Lee JJ.
 535 Genetic and neural bases of the neuroticism general factor. *Biol Psychol* 2023;
 536 184: 108692.
- 537 42. Nievergelt CM, Maihofer AX, Atkinson EG, Chen CY, Choi KW, Coleman JRI *et al.* Genome-wide association analyses identify 95 risk loci and provide insights into the neurobiology of post-traumatic stress disorder. *Nat Genet* 2024; **56**(5): 792-808.
- 541 43. Trubetskoy V, Pardinas AF, Qi T, Panagiotaropoulou G, Awasthi S, Bigdeli TB *et*542 *al.* Mapping genomic loci implicates genes and synaptic biology in schizophrenia.
 543 *Nature* 2022; **604**(7906): 502-508.
- 544 44. Okbay A, Baselmans BM, De Neve JE, Turley P, Nivard MG, Fontana MA *et al.*545 Genetic variants associated with subjective well-being, depressive symptoms, and neuroticism identified through genome-wide analyses. *Nat Genet* 2016;
 547 48(6): 624-633.
- 548 45. Ge T, Chen C-Y, Ni Y, Feng Y-CA, Smoller JW. Polygenic prediction via Bayesian regression and continuous shrinkage priors. *Nature Communications* 2019;
 550 **10**(1): 1776.
- 551 46. Balduzzi S, Rucker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. *Evid Based Ment Health* 2019; **22**(4): 153-160.
- 47. Bailey AJ, McHugh RK. Why do we focus on the exception and not the rule?
 554 Examining the prevalence of mono- versus polysubstance use in the general population. *Addiction* 2023; **118**(10): 2026-2029.
- Hatoum AS, Johnson EC, Colbert SMC, Polimanti R, Zhou H, Walters RK *et al.*The addiction risk factor: A unitary genetic vulnerability characterizes substance use disorders and their associations with common correlates. *Neuropsychopharmacology* 2022; **47**(10): 1739-1745.
- 49. Hatoum AS, Colbert SMC, Johnson EC, Huggett SB, Deak JD, Pathak G *et al.*Multivariate genome-wide association meta-analysis of over 1 million subjects

- identifies loci underlying multiple substance use disorders. *Nat Ment Health*2023; 1(3): 210-223.
- 564 50. Patrick ME, Berglund PA, Joshi S, Bray BC. A latent class analysis of heavy
 565 substance use in Young adulthood and impacts on physical, cognitive, and
 566 mental health outcomes in middle age. *Drug Alcohol Depend* 2020; **212:** 108018.
- 567 51. Schepis TS, McCabe SE. The latent class structure of substance use in US adults 50 years and older. *Int J Geriatr Psychiatry* 2021; **36**(12): 1867-1877.
- 569 52. Agrawal A, Lynskey MT, Madden PA, Bucholz KK, Heath AC. A latent class
 570 analysis of illicit drug abuse/dependence: results from the National
 571 Epidemiological Survey on Alcohol and Related Conditions. *Addiction* 2007;
 572 102(1): 94-104.
- 573 53. Chan G, Connor J, Hall W, Leung J. The changing patterns and correlates of
 574 population-level polysubstance use in Australian youth: a multi-group latent class
 575 analysis of nationally representative samples spanning 12 years. *Addiction* 2020;
 576 115(1): 145-155.
- 577 54. Rodriguez AS, Robinson LD, Kelly PJ, Hudson S. Polysubstance use classes
 578 and health outcomes among women attending specialist substance use
 579 treatment services. *Drug Alcohol Rev* 2022; **41**(2): 488-500.
- 580 55. Mulder RH, Neumann A, Cecil CAM, Walton E, Houtepen LC, Simpkin AJ *et al.*581 Epigenome-wide change and variation in DNA methylation in childhood:
 582 trajectories from birth to late adolescence. *Hum Mol Genet* 2021; **30**(1): 119-134.
- 583 56. Li Z, Xu K, Zhao S, Guo Y, Chen H, Ni J *et al.* SPATA4 improves aging-induced 584 metabolic dysfunction through promotion of preadipocyte differentiation and 585 adipose tissue expansion. *Aging Cell* 2021; **20**(1): e13282.
- 586 57. Islam SA, Goodman SJ, MacIsaac JL, Obradovic J, Barr RG, Boyce WT *et al.*587 Integration of DNA methylation patterns and genetic variation in human pediatric
 588 tissues help inform EWAS design and interpretation. *Epigenetics Chromatin*589 2019; **12**(1): 1.
- 590 58. Spiers H, Hannon E, Schalkwyk LC, Smith R, Wong CC, O'Donovan MC *et al.*591 Methylomic trajectories across human fetal brain development. *Genome Res*592 2015; **25**(3): 338-352.
- 593 59. Inkster AM, Yuan V, Konwar C, Matthews AM, Brown CJ, Robinson WP. A cross594 cohort analysis of autosomal DNA methylation sex differences in the term
 595 placenta. *Biol Sex Differ* 2021; **12**(1): 38.
- 596 60. Zhang L, Silva TC, Young JI, Gomez L, Schmidt MA, Hamilton-Nelson KL *et al.*597 Epigenome-wide meta-analysis of DNA methylation differences in prefrontal
 598 cortex implicates the immune processes in Alzheimer's disease. *Nat Commun*599 2020; **11**(1): 6114.
- 60061.Tsai PC, Glastonbury CA, Eliot MN, Bollepalli S, Yet I, Castillo-Fernandez JE et601al. Smoking induces coordinated DNA methylation and gene expression changes

- in adipose tissue with consequences for metabolic health. *Clin Epigenetics* 2018; **10**(1): 126.
- 604 62. Harper JD, Fan KH, Aslam MM, Snitz BE, DeKosky ST, Lopez OL *et al.* Genome605 Wide Association Study of Incident Dementia in a Community-Based Sample of
 606 Older Subjects. *J Alzheimers Dis* 2022; **88**(2): 787-798.
- 607 63. He L, Loika Y, Park Y, Genotype Tissue Expression c, Bennett DA, Kellis M *et al.*608 Exome-wide age-of-onset analysis reveals exonic variants in ERN1 and SPPL2C
 609 associated with Alzheimer's disease. *Transl Psychiatry* 2021; **11**(1): 146.
- 610 64. Lampada A, Taylor V. Notch signaling as a master regulator of adult 611 neurogenesis. *Front Neurosci* 2023; **17:** 1179011.
- 612 65. Ni T, Zhu L, Wang S, Zhu W, Xue Y, Zhu Y *et al.* Medial prefrontal cortex Notch1
 613 signalling mediates methamphetamine-induced psychosis via Hes1-dependent
 614 suppression of GABA(B1) receptor expression. *Mol Psychiatry* 2022; **27**(10):
 615 4009-4022.
- 616 66. Latypova X, Vincent M, Molle A, Adebambo OA, Fourgeux C, Khan TN *et al.*617 Haploinsufficiency of the Sin3/HDAC corepressor complex member SIN3B
 618 causes a syndromic intellectual disability/autism spectrum disorder. *Am J Hum*619 *Genet* 2021; **108**(5): 929-941.
- 620 67. Moffat JJ, Jung EM, Ka M, Jeon BT, Lee H, Kim WY. Differential roles of ARID1B
 621 in excitatory and inhibitory neural progenitors in the developing cortex. *Sci Rep*622 2021; **11**(1): 3856.
- 623 68. Zhu G, Liu J, Li Y, Huang H, Chen C, Wu D *et al.* ARID1B Deficiency Leads to 624 Impaired DNA Damage Response and Activated cGAS-STING Pathway in Non-625 Small Cell Lung Cancer. *J Cancer* 2024; **15**(9): 2601-2612.
- 626 69. Carnes MU, Quach BC, Zhou L, Han S, Tao R, Mandal M *et al.* Smoking627 informed methylation and expression QTLs in human brain and colocalization
 628 with smoking-associated genetic loci. *medRxiv* 2023.
- 629 70. Cardenas A, Ecker S, Fadadu RP, Huen K, Orozco A, McEwen LM *et al.*630 Epigenome-wide association study and epigenetic age acceleration associated
 631 with cigarette smoking among Costa Rican adults. *Sci Rep* 2022; **12**(1): 4277.
- Mishra PP, Mishra BH, Raitoharju E, Mononen N, Viikari J, Juonala M *et al.* Gene
 Set Based Integrated Methylome and Transcriptome Analysis Reveals Potential
 Molecular Mechanisms Linking Cigarette Smoking and Related Diseases. *OMICS* 2023; **27**(5): 193-204.
- 636 72. Ponomarev I. Epigenetic control of gene expression in the alcoholic brain.
 637 Alcohol Res 2013; 35(1): 69-76.
- 638 73. Dugue PA, Wilson R, Lehne B, Jayasekara H, Wang X, Jung CH *et al.* Alcohol
 639 consumption is associated with widespread changes in blood DNA methylation:
 640 Analysis of cross-sectional and longitudinal data. *Addict Biol* 2021; 26(1):
 641 e12855.

- Liu C, Marioni RE, Hedman AK, Pfeiffer L, Tsai PC, Reynolds LM *et al.* A DNA
 methylation biomarker of alcohol consumption. *Mol Psychiatry* 2018; 23(2): 422433.
- 645 75. Skariah G, Seimetz J, Norsworthy M, Lannom MC, Kenny PJ, Elrakhawy M *et al.*646 Mov10 suppresses retroelements and regulates neuronal development and
 647 function in the developing brain. *BMC Biol* 2017; **15**(1): 54.
- 648 76. Hofer E, Roshchupkin GV, Adams HHH, Knol MJ, Lin H, Li S *et al.* Genetic
 649 correlations and genome-wide associations of cortical structure in general
 650 population samples of 22,824 adults. *Nat Commun* 2020; **11**(1): 4796.
- 651 77. Grasby KL, Jahanshad N, Painter JN, Colodro-Conde L, Bralten J, Hibar DP *et al.* The genetic architecture of the human cerebral cortex. *Science* 2020;
 653 367(6484).
- 654 78. Sha Z, Schijven D, Fisher SE, Francks C. Genetic architecture of the white 655 matter connectome of the human brain. *Sci Adv* 2023; **9**(7): eadd2870.
- Schreiber R, Ousingsawat J, Wanitchakool P, Sirianant L, Benedetto R, Reiss K *et al.* Regulation of TMEM16A/ANO1 and TMEM16F/ANO6 ion currents and
 phospholipid scrambling by Ca(2+) and plasma membrane lipid. *J Physiol* 2018; **596**(2): 217-229.
- 80. Sikdar S, Joehanes R, Joubert BR, Xu CJ, Vives-Usano M, Rezwan FI *et al.*Comparison of smoking-related DNA methylation between newborns from
 prenatal exposure and adults from personal smoking. *Epigenomics* 2019; **11**(13):
 1487-1500.
- 81. Joehanes R, Just AC, Marioni RE, Pilling LC, Reynolds LM, Mandaviya PR *et al.*Epigenetic Signatures of Cigarette Smoking. *Circ Cardiovasc Genet* 2016; 9(5):
 436-447.
- 667 82. Kinare V, Pal S, Tole S. LDB1 Is Required for the Early Development of the 668 Dorsal Telencephalon and the Thalamus. *eNeuro* 2019; **6**(1).
- Monahan K, Horta A, Lomvardas S. LHX2- and LDB1-mediated trans interactions
 regulate olfactory receptor choice. *Nature* 2019; 565(7740): 448-453.
- 84. Towers EB, Shapiro DA, Abel JM, Bakhti-Suroosh A, Kupkova K, Auble DT *et al.*672 Transcriptional Profile of Exercise-Induced Protection Against Relapse to
 673 Cocaine Seeking in a Rat Model. *Biol Psychiatry Glob Open Sci* 2023; 3(4): 734674 745.
- 85. Philibert R, Dogan M, Beach SRH, Mills JA, Long JD. AHRR methylation predicts
 smoking status and smoking intensity in both saliva and blood DNA. *Am J Med Genet B Neuropsychiatr Genet* 2020; **183**(1): 51-60.

678 86. Milivojevic V, Sinha R. Central and Peripheral Biomarkers of Stress Response for 679 Addiction Risk and Relapse Vulnerability. *Trends Mol Med* 2018; **24**(2): 173-186.

- 680 87. Levis SC, Baram TZ, Mahler SV. Neurodevelopmental origins of substance use
 681 disorders: Evidence from animal models of early-life adversity and addiction. *Eur*682 *J Neurosci* 2022; **55**(9-10): 2170-2195.
- 88. Bart CP, Titone MK, Ng TH, Nusslock R, Alloy LB. Neural reward circuit
 dysfunction as a risk factor for bipolar spectrum disorders and substance use
 disorders: A review and integration. *Clin Psychol Rev* 2021; **87:** 102035.
- 88. Zeng J, You L, Yang F, Luo Y, Yu S, Yan J *et al.* A meta-analysis of the neural
 substrates of monetary reward anticipation and outcome in alcohol use disorder. *Hum Brain Mapp* 2023; **44**(7): 2841-2861.
- 689 90. Peechatka AL, Whitton AE, Farmer SL, Pizzagalli DA, Janes AC. Cigarette
 690 craving is associated with blunted reward processing in nicotine-dependent
 691 smokers. *Drug Alcohol Depend* 2015; **155**: 202-207.

692

N = 31,197 (average age 42 yrs ± 11; Females = 49%)





cg02833127 (SPATA4)

AD-TD vs Controls Weight Weight 95%-CI P-value (common) (random) Cohort MD AFR -0.330 [-0.429; -0.231] < 0.01 36.7% 38.8% -AMR -0.474 [-0.764; -0.184] < 0.01 4.3% EUR -0.595 [-0.673; -0.517] < 0.01 59.0% 40.5% -0.492 [-0.552; -0.432] < 0.01 100.0% Common effect model Random effects model -0.467 [-0.649; -0.285] < 0.01 -- 100.0% - 18% , p = 0.3 -14

Test for overall effect (common effect): z = -16.08 (p < 0.01)

Test for overall effect (random effects): z = -5.03 (p < 0.01)

CD-TD vs Controls



Test for overall effect (random effects): z = -6.15 (p < 0.01)

PSU vs Controls				Weight	Weight
ohort	MD	95%-CI	P-value	(common)	(random)
FR	-0.220	[-0.359; -0.080	< 0.01	26.1%	26.1%
MR	-0.225	[-0.518; 0.067]	0.13	5.9%	5.9%
UR —	-0.251	[-0.338; -0.165]	< 0.01	67.9%	67.9%
ommon effect model	-0.241	[-0.313; -0.170]	< 0.01	100.0%	
andom effects model	-0.241	[-0.313; -0.170]	< 0.01		100.0%
storagonity 12-05, 9-653 -0.5 -0.5	0 12 04				
est for overall effect (common effect): z = -6.64	< 0.01)				
and for a small affect (and an affectal)	-0.01.)				

cg08355353 (MOV10)

CD-TD vs Controls				Weight	Weight
Cohort	MD	95%-CI	P-value	(common)	(random)
AFR	0.316	[-0.010; 0.641]	0.06	23.8%	23.8%
EUR —	• 0.467	[0.285; 0.649]	< 0.01	76.2%	76.2%
Common effect model	0.431	[0.272; 0.590]	< 0.01	100.0%	
Random effects model	0.431	[0.272; 0.590]	< 0.01		100.0%
Heterogeneity: 1 ¹ -05 , p = 1.47 -0,6 -0,4 -0,7 3 0,7 0	4 0.6				
Test for overall effect (common effect): $z = 5.32$ (p < 0.01)					
Test for overall effect (random effects): z = 5.32 (p < 0.01)					

cg09909775 (ANO6)

CD-TD vs Controls				Weight	Weight
Cohort	MD	95%-CI	P-value	(common)	(random)
AFR	.419	[0.020; 0.819]	0.04	22.0%	22.0%
- UR	0.519	[0.307; 0.731]	< 0.01	78.0%	78.0%
ommon effect model -	0.497	[0.310; 0.684]	< 0.01	100.0%	
tandom effects model -	0.497	[0.310; 0.684]	< 0.01		100.0%
leterogenetic: 1 ² + 0% , p + 0.07 -0.5 0	0.5				
est for overall effect (common effect): z = 5.20 (p < 0.01)					
est for overall effect (random effects): z = 5.20 (p < 0.01)					

cg19436567 (ARID1B)

AD-TD vs Controls

20.7%



Weight Weight

Test for overall effect (random effects): z = 5.70 (p < 0.01)

cg06815056 (SIN3B)

AD-TD vs Controls							Weight	Weight
Cohort				MD	95%-CI I	P-value (common)	(random)
AFR				0.217	[0.081; 0.354]	< 0.01	35.9%	35.9%
AMR		\rightarrow		0.513	[0.052; 0.975]	0.03	3.2%	3.2%
EUR		+		0.227	[0.122; 0.332]	< 0.01	60.9%	60.9%
Common effect model		-		0.233	[0.151; 0.315]	< 0.01	100.0%	
Random effects model		-		0.233	[0.151; 0.315]	< 0.01		100.0%
Heterogeneity: $l^2 \ast 0 \Sigma$, $p \ast 1.48$	-0.5 0	1	5					
Test for overall effect (common effect):	z = 5.56 (p < 0.	01)						
Yest for morall offect (and an effect)		on)						

cg13725899 (NOTCH1)

AD-TD vs Con	trols								Weight	Weight
Cohort						MD	95%-CI	P-value	(common)	(random
AFR				\rightarrow		0.298	[0.153; 0.443]	< 0.01	41.2%	41.2%
AMR						-0.064	[-0.427; 0.299]	0.73	6.6%	6.6%
EUR					•—	0.301	[0.172; 0.430]	< 0.01	52.2%	52.2%
Common effect model				-	>	0.276	[0.183; 0.369]	< 0.01	100.0%	
Random effects model				-	>	0.276	[0.183; 0.369]	< 0.01		100.0%
mesospecity: 1 ¹ +445, , p = 0.17	-2.4	0.2		0.2	64					
Test for overall effect (comm	on effect):	z = 5.81	(p < 0.01)							
			S							

cg20270863 (C1orf133/SERTAD4)

AD-TD vs Controls				Weight	Weight
Cohort	MD	95%-CI	P-value	(common)	(random)
AFR -	0.195	[0.101; 0.289]	< 0.01	36.4%	36.4%
AMR	0.090	[-0.176; 0.357]	0.51	4.6%	4.6%
EUR —	• 0.145	[0.071; 0.219]	< 0.01	59.0%	59.0%
Common effect model	0.161	[0.104; 0.217]	< 0.01	100.0%	
Random effects model -	O.161	[0.104; 0.217]	< 0.01		100.0%
Haterogeneity: 12 - 05 , p - 0.62 - 0.3 - 0.2 - 0.1 0 0.1	0.2 0.3				
Test for overall effect (common effect): $z = 5.53 (p < 0.01)$					
Test for overall effect (random effects): $z = 5.53$ (p < 0.01)					

